You are here: Home » PTI Stories » National » News
Business Standard

Jubilant Pharma gets USFDA nod for Symmetrel's generic version

Press Trust of India  |  New Delhi 

Drug firm today said its subsidiary has received final approval from the US health regulator for Hydrochloride tablets, an anti-viral and

The approved drug, generic version of of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of caused by various strains of virus. It is also indicated in the treatment of and drug-induced extrapyramidal reactions.

"Jubilant Pharma Ltd, a material wholly of the company, through one of its wholly owned subsidiaries, has received abbreviated new drug application (ANDA) final approval for Hydrochloride tablets, 100 mg," said in a filing.

This is the ninth approval received by the company from the USFDA during the current financial year.

As on December 31, 2017, had 86 ANDAs for oral solids filed in the US, of which 56 have been approved and 12 injectable filings, of which 10 had been approved, the filing added.

Shares of the company were trading 1.18 per cent down at Rs 956.95 on the

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, February 09 2018. 12:35 IST